Form 8-K - Current report:
SEC Accession No. 0001104659-25-055242
Filing Date
2025-06-02
Accepted
2025-06-02 08:25:16
Documents
14
Period of Report
2025-06-02
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2516829d1_8k.htm   iXBRL 8-K 25788
2 EXHIBIT 99.1 tm2516829d1_ex99-1.htm EX-99.1 25837
6 GRAPHIC tm2516829d1_ex99-1img001.jpg GRAPHIC 14254
  Complete submission text file 0001104659-25-055242.txt   244107

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA qure-20250602.xsd EX-101.SCH 3011
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE qure-20250602_lab.xml EX-101.LAB 34239
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE qure-20250602_pre.xml EX-101.PRE 22356
16 EXTRACTED XBRL INSTANCE DOCUMENT tm2516829d1_8k_htm.xml XML 3600
Mailing Address PAASHEUVELWEG 25A AMSTERDAM P7 1105 BP
Business Address PAASHEUVELWEG 25A AMSTERDAM P7 1105 BP 1-339-970-7000
uniQure N.V. (Filer) CIK: 0001590560 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36294 | Film No.: 251013203
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)